Some effects. Orders of magnitude less than smoking. Mostly reversible.

Research shows some inflammatory effects from vape but substantially less than smoking. Studies document mild acute airway inflammation, some systemic inflammation markers plus mild oxidative stress. However these effects are orders of magnitude lower than smoking-induced inflammation which is driven by thousands of combustion chemicals. Ex-smokers who switch to vape typically show reduced inflammation markers compared to continued smoking. Full cessation produces further inflammation reduction. Long-term vape inflammation patterns still being characterised as modern vape emerged around 2007. Here is the current state of inflammation research plus how vape compares to smoking. For the specific lung effects see our lung guide. This article is general consumer information, not medical advice.

What is inflammation and why it matters

Inflammation is a key biological process relevant to many chronic conditions:

What inflammation is.

• Body immune response to damage, irritation or pathogens.
• Acute inflammation: helpful healing response.
• Chronic inflammation: persistent low-grade immune activation.
• Chronic inflammation associated with disease development.

Why it matters for vape research.

• Smoking causes severe chronic inflammation driving most smoking disease.
• Any substance inhaled may cause some inflammation.
• Inflammation markers are measurable proxies for harm.
• Chronic inflammation linked to cardiovascular disease, cancer, COPD, diabetes, autoimmune conditions.

Common inflammation markers.

• C-reactive protein (CRP): general inflammation marker.
• Cytokines (IL-6, TNF-alpha, IL-8): specific inflammatory signalling molecules.
• White blood cell markers: immune activation indicators.
• Oxidative stress markers: cellular damage from free radicals.
• Endothelial dysfunction markers: blood vessel inflammation.
• Platelet activation markers: clotting-related inflammation.

Smoking inflammation baseline

Understanding smoking inflammation helps contextualise vape findings:

Smoking produces.

• Severe chronic airway inflammation driving COPD.
• Systemic inflammation measurable throughout body.
• Cardiovascular inflammation driving atherosclerosis.
• Oral and gum inflammation.
• Reproductive tissue inflammation.
• Chronic oxidative stress.
• Elevated CRP typically 2-3x non-smoker levels.
• Cytokine dysregulation.

What drives smoking inflammation.

• Tar deposition in airways.
• Carbon monoxide cellular effects.
• Thousands of reactive compounds in smoke.
• Particulate matter irritation.
• Specific toxins triggering immune activation.
• Cumulative damage over decades.

Smoking inflammation outcomes.

• COPD (chronic obstructive pulmonary disease).
• Atherosclerosis leading to heart attacks plus strokes.
• Periodontal disease.
• Multiple cancers via chronic inflammation.
• Increased infection susceptibility.
• Accelerated aging.

This is the severe inflammatory burden vape is compared against.

What research shows about vape inflammation

Studies in vapers have measured various inflammation markers:

Acute airway inflammation.

• Some mild local inflammation in airways.
• Less severe than smoking acute effects.
• Usually resolves between sessions.
• Individual sensitivity varies.

Systemic CRP plus cytokines.

• Some studies show mild elevations compared to non-users.
• Much lower than smoker elevations.
• Often overlapping with non-user range.
• Clinical significance of mild elevation less clear than smoking.

Oxidative stress.

• Some measurable increases in oxidative stress markers.
• Less than smoking oxidative burden.
• Flavour compounds may contribute variably.
• Vape device plus ingredient quality affects this.

Endothelial function.

• Some mild acute effects on blood vessel function.
• Nicotine-mediated primarily.
• Less severe than smoking endothelial damage.

Immune cell markers.

• Some differences from non-users documented.
• Nature and significance less clear than smoking immune effects.
• Individual variation significant.

Overall magnitude.

• Generally mild compared to smoking.
• Orders of magnitude difference in most markers.
• Not zero but much reduced.
• Long-term chronic effects still being characterised.

How vape inflammation compares to smoking

Direct comparison across inflammation categories:

Airway inflammation.

• Smoking: severe chronic inflammation driving COPD, chronic bronchitis.
• Vape: mild effects usually, no equivalent chronic disease pattern.
• Switchers typically see airway inflammation reduction.

Cardiovascular inflammation.

• Smoking: major driver of atherosclerosis plus heart disease.
• Vape: some effects from nicotine but much less than smoking.
• Cardiovascular risk much lower than continued smoking.

Systemic markers.

• Smoking: CRP typically 2-3x non-smoker levels chronically.
• Vape: mild elevations, often within non-smoker range.
• Much closer to non-smoker pattern than smoker pattern.

Oxidative stress.

• Smoking: severe oxidative burden from combustion.
• Vape: modest effects from heating plus chemistry.
• Orders of magnitude less than smoking.

Oral inflammation.

• Smoking: severe gum disease, periodontitis.
• Vape: mild effects, much less severe.
• Switching typically improves oral inflammation.

Ex-smoker switchers: inflammation trajectory

What happens to inflammation when smokers switch to vape:

Within days.

• Carbon monoxide clears (reduces inflammatory trigger).
• Acute inflammatory response to smoking stops.
• Some airway irritation (different profile, usually mild).

Within weeks.

• CRP beginning to decrease.
• Airway inflammation markers improving.
• Initial smoker flu (paradoxical increased cough as lungs clear residue).
• Cardiovascular inflammation beginning reduction.

Within months.

• Substantial CRP reduction.
• Cytokine profiles improving.
• Oxidative stress reducing.
• Endothelial function improving.
• Measurable inflammation reduction compared to continued smoking.

Within a year.

• Many inflammation markers approaching non-smoker levels.
• Some residual effects from nicotine plus vape remain.
• Substantial improvement from smoking baseline.

Long-term.

• Continued inflammation reduction.
• Established smoking inflammatory damage may persist partially.
• New inflammation from vape limited.
• Full cessation further improves.

Factors affecting vape inflammation

Individual variation in vape inflammation depends on multiple factors:

Product quality.

• UK TPD-compliant products excluding banned substances.
• Pharmaceutical-grade ingredients.
• Quality manufacturing.
• Non-compliant products may have more inflammatory compounds.

Device type.

• Temperature of heating matters (higher temperatures produce more thermal breakdown products).
• Coil type plus material.
• Airflow plus vapour volume.

Use patterns.

• Heavier use produces more cumulative effects.
• Chain vaping versus spaced sessions.
• Session duration.

Flavour compounds.

• Some flavour compounds more inflammatory than others.
• UK TPD bans specifically concerning compounds.
• Simpler flavour profiles often better.

Individual factors.

• Genetic variation in inflammatory response.
• Baseline health.
• Other lifestyle factors (diet, exercise, stress).
• Existing inflammatory conditions.

Concurrent smoking (dual use).

• Continuing to smoke alongside vape maintains smoking inflammation.
• Full switch needed for maximum inflammation reduction.

Long-term uncertainty

Honest acknowledgment of what we do not yet know:

Decades-long data still developing.

• Modern vape emerged around 2007.
• 15+ year users provide emerging long-term data.
• 20+ year data still coming.
• Full chronic inflammation effects uncertain.

Specific scenarios less studied.

• Very heavy daily use over decades.
• Specific flavour compound chronic exposure.
• Individual susceptibility variation over time.
• Interaction with other lifestyle factors.

What mechanism predicts.

• Absence of combustion products should translate to much less chronic inflammation than smoking.
• This prediction supported by available data.
• Magnitude of chronic effects still being established.

Research priorities.

• Longitudinal studies continuing.
• Long-term cohort research.
• Specific marker tracking over years.
• Ongoing evidence reviews.

Reducing inflammation impact

Practical steps for vape users concerned about inflammation:

Product choice.

• UK TPD-compliant products with regulatory protection.
• Reputable brands with ingredient disclosure.
• Simpler flavour profiles often lower compound exposure.

Usage patterns.

• Lower nicotine strength reduces some effects.
• Spaced sessions rather than chain vaping.
• Step down over time.

General health.

• Healthy diet (anti-inflammatory foods: omega-3, antioxidants).
• Regular exercise (reduces systemic inflammation).
• Adequate sleep (inflammatory regulation).
• Manage stress (chronic stress pro-inflammatory).
• Avoid other inflammatory factors (excess alcohol, processed foods).

Monitor symptoms.

• Respiratory symptoms warrant GP review.
• New cardiovascular symptoms need assessment.
• Persistent fatigue or other systemic symptoms worth investigating.

Full cessation.

• Best long-term option for minimising inflammation.
• NHS Stop Smoking Services support cessation.
• Most vape inflammation reverses after cessation.

Practical approach

• Some inflammation effects from vape but much less than smoking.
• Orders of magnitude difference from smoking inflammatory burden.
• Ex-smokers switching see substantial reduction in inflammation markers.
• Most vape inflammation appears reversible with cessation.
• Long-term uncertainty continues as decades-long data develops.
• UK TPD-compliant products minimise concerning compounds.

For those managing vape use with concerns about inflammation, our nicotine salts collection features UK TPD-compliant products excluding banned substances, across every legal strength from 20mg down to 3mg supporting step-down toward cessation.

For the wider view on vape, inflammation plus long-term health questions, our full health hub covers every major question UK readers ask.